Source comparison
Tesamorelin + Ipamorelin Blend Visceral Fat Results Timeline | Protocol Comparison
8 weeks 1mg once daily 200mcg 2× daily 5–8% (early responders only) Modest improvements in fasting insulin; waist circumference −1.5cm average Too short for statistically significant VAT reduction. Imaging changes minimal 12 weeks 1–2mg once daily 200–300mcg 2
This comparison does not assign a generated winner or score.
- 8 weeks
- 1mg once daily
- 200mcg 2× daily
- 5–8% (early responders only)
- Modest improvements in fasting insulin; waist circumference −1.5cm average
- Too short for statistically significant VAT reduction. Imaging changes minimal
- 12 weeks
- 1–2mg once daily
- 200–300mcg 2–3× daily
- 10–15%
- Fasting glucose ↓ 8–12 mg/dL; HOMA-IR improves 15–20%; liver enzymes normalize in NAFLD
- Minimum viable timeline for imaging-confirmed VAT loss. Standard research endpoint
- 24 weeks
- 2mg once daily
- 300mcg 3× daily
- 18–25%
- Sustained insulin sensitivity; triglycerides ↓ 20–30%; subcutaneous fat ↓ 8–12%
- Optimal balance of efficacy and safety. Plateau begins here without adjunct interventions
- 52 weeks
- 20–28% (diminishing returns after week 26)
- Stable metabolic improvements; lean mass preservation or modest gain
- Extended protocols safe in clinical trials but require monitoring for GH-related side effects